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Acting Opioid (LAO) medication for chronic pain management.
The LAOs considered were transdermal fentanyl (TF), controlled
release morphine sulfate (CRMS) and controlled release oxy-
codone (CRO). METHODS: Medicaid beneﬁciaries from three
states during 1999–2000 were studied. Patients were followed
for at least one year, starting with their ﬁrst LAO prescription in
1999. Patients who did not have a LAO in the six months prior
to that index date were labeled “incident”, while patients with
a history of LAO use were labeled as “prevalent”. Patients were
then grouped by the opioid they received on the index date.
Disease-type, demographics, health status, health care utiliza-
tion, and expenditures were measured and compared among the
three LAO cohorts. LAO costs and total annual health care
expenditures by LAO cohort were compared using descriptive
and multivariate analyses, for the incident and prevalent patient
samples. RESULTS: Descriptive results indicate that incident (I)
and prevalent (P) LOA annual cost for CRO ($1361 I; $4146 P)
were signiﬁcantly higher than costs observed for TF ($1202 I;
$3061 P) or CRMS ($919 I; $3572 P) (p < 0.01). After control-
ling for confounding characteristics, total annual health expen-
ditures in the CRO incidence sample were similar to the CRMS
sample. However, total annual health care expenditures for the
CRO population were signiﬁcantly lower than expenditures for
the TF population, with an annual cost savings of about $960
(p < 0.01). Economic differences were not noted among the
prevalent LAO populations. CONCLUSIONS: Total cost, not
just pharmaceutical costs, should be considered when making
policy decisions about insurance coverage for LAO drugs. In the
incident sample, patients on TF cost about $960 more per year
(p < 0.01), on average, compared to similar CRMS and CRO
patients.
PPN5
AN OPIATE RENEWAL CLINIC:A COST EFFECTIVE
APPROACH TO REDUCING UNSCHEDULED PATIENT VISITS
Sampson JM, Goldenson AC, Swanson SA
VA Medical Center, Gainesville, FL, USA
OBJECTIVES: The number of patients on opiates for chronic
non-malignant pain continues to grow. With an emphasis on
treating pain, opiate medication is being used more often. Fol-
lowing patients in a Primary care clinic has become more difﬁ-
cult because of the increased time required to manage and assess
medication effects and the large number of unscheduled walk-in
visits. Our objectives were to reduce unscheduled walk-in visits,
reduce substance abuse, and diversion. METHODS: We estab-
lished a multidisciplianry opiate renewal clinic that meets once
a week and sees between 20–50 patients in a group education
setting. A thirty minute educational presentation is made each
session; all patients undergo urine drug testing and blood work.
Patients who are negative for prescribed medication receive a one
week renewal and return date to rule out diversion. Patients who
have street drugs present are referred for Substance abuse coun-
seling and given a one week renewal. Patients who are impaired
do not receive medication and appropriate referral is made.
Patients who are compliant may receive a one month renewal
and face-to-face vists every two months. RESULTS: Unscheduled
walk-in visits decreased by 76%. Referrals for substance abuse
treatment increased by 100%. It was previously difﬁcult to diag-
nose substance abuse without drug testing. Approximately 32%
of patients had positive urine for marijuana, cocaine or both.
CONCLUSIONS: An Opiate renewal clinic for patients with
chronic non-maligant pain and substance abuse can be a cost
effective approach to management.
PAIN
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RELATIONSHIP BETWEEN PAIN AND PERCEIVED 
HEALTH STATUS IN OLDER PERSONS WITH 
POST-HERPETIC NEURALGIA
Oster G1, Dukes E2, Edelsberg J1, Cleary P3
1Policy Analysis Inc. (PAI), Brookline, MA, USA; 2Pﬁzer Inc, New York,
NY, USA; 3Harvard Medical School, Boston, MA, USA
OBJECTIVE: Post-herpetic neuralgia (PHN, persistent pain fol-
lowing “shingles”) is common, especially among older persons.
The pain often lasts well beyond the acute episode, occasionally
lasting for several years. This study explored the impact of
chronic pain on perceived health status in patients with PHN.
METHODS: This was a community-based survey where persons
aged ≥65 years with PHN were recruited via advertisements in
24 large US newspapers. Eligible subjects were sent a question-
naire to complete, which included items concerning PHN pain
intensity in the prior week (current, average, worse, least), the
EQ-5D, and a 100-point global health rating scale. RESULTS:
A total of 385 persons participated in the study; 61% were age
≥75 years. Mean (±SD) current, average, worst, and least pain
due to PHN was 4.0 (±2.7), 4.6 (±2.1), 6.0 (±2.4), and 2.9 (±2.3)
respectively. Mean values for the EQ-5D weighted health index
and the global health rating scale were 0.61 (±0.26) and 65.7
(±21.1). There was a strong relationship between pain intensity
and overall health rating. Subjects with “mild” worst pain
(range: 0–4) had a mean health rating of 73.8 (±17.5), while
those with “moderate” (range: 4–<7) or “severe” (range: 7–10)
worst pain had mean values of 65.2 (±21.0) and 60.5 (±22.6)
respectively. Similar results were obtained for other measures of
pain intensity. The EQ-5D weighted health index varied in a
similar fashion in relation to pain intensity. Subjects with “mild”
average pain had a mean EQ-5D weighted health index score of
0.69 (±0.17) while those with “moderate” or “severe” average
pain had mean values of 0.58 (±0.27) and 0.25 (±0.31) respec-
tively. CONCLUSIONS: Pain intensity due to PHN is substan-
tial and has a profound impact on self-reported health.
PAIN
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PPN7
TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINED-
RELEASE OPIOID ANALGESICS: A REVISIT
Novak S1, Nemeth WC2, Lawson KA1
1University of Texas at Austin, Austin,TX, USA; 2Texas Worker’s
Compensation Commission, Austin,TX, USA
OBJECTIVES: Previous literature suggests that increases in the
medical use of opioids over the early 1990s did not contribute
to increased morbidity secondary to opioid abuse. Our objective
was to evaluate the period 1997–2001 to analyze trends in
medical use and medical abuse of three classes of opioid anal-
gesics that are commonly used in sustained-release formulations:
fentanyl, morphine, and oxycodone. METHODS: A retrospec-
tive analysis of the Drug Abuse Warning Network (DAWN) data-
base and the Automation of Reports and Consolidation Order
System (ARCOS) database for the years 1997–2001 was used
for this study. RESULTS: The analysis of the DAWN database
showed that there was an 83.5% increase in all opioid analgesic
mentions from 1997 to 2001. Mentions involving any fentanyl
compound increased 249.8%, any morphine compound
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increased 161.8%, and any oxycodone-containing compound
increased 267.3%. Mentions of each of these three classes of
opioids remained less than 2% of all total drug mentions per
year for each year studied. Medical use of the selected opioid
classes, as reported in the ARCOS database and measured by
grams distributed, all increased substantially (fentanyl 151.2%,
morphine 48.8%, oxycodone 347.9%). CONCLUSIONS: Using
this method of analysis, the rates of drug abuse, and resultant
morbidity secondary to the use of opioid analgesics, remains low
in spite of the increase in medical use of these substances.
PPN8
PATTERNS AND TRENDS IN OPIOID USE AMONG
INDIVIDUALS WITH BACK PAIN IN THE UNITED STATES
Luo X1, Pietrobon R2, Hey L1
1Duke University Medical Center, Durham, NC, USA
Secondary analysis of the Medical Expenditure Panel Survey
(MEPS) from 1996 to 1999. OBJECTIVE: To examine patterns
in opioid use in 1996, 1997, 1998 and 1999 among individuals
with back pain in the US, and to investigate trends in the use of
overall and individual opioid category. No study has examined
at a national level the patterns and trends of opioid use among
individuals with back pain. METHODS: Individuals with back
pain were stratiﬁed by socio-demographic characteristics and
geographical regions. Rates of overall opioid use were compared
among different strata. To investigate trends in opioid use, use
rates of the overall and individual opioid category were calcu-
lated and compared. From 1996 to 1999, the use of opioid was
not signiﬁcantly different across different gender or racial/ethni-
cal groups, but signiﬁcantly higher among individuals who were
publicly insured, had low or below low income and had educa-
tion at or below 12th grade compared to their respective coun-
terparts. During the 4-year period, signiﬁcant variations in
opioid use across different age groups or geographic regions 
were observed in early years. But the variations became non-
signiﬁcant in later years. RESULTS: Trend analysis indicated that
the rates of overall opioid use increased slightly across the 4-year
span. Among individual opioid categories, the use of oxycodone
or hydrocodone increased whereas the use of propoxyphene
decreased. CONCLUSIONS: The signiﬁcantly higher use of
opioids among individuals who were publicly insured, had low
or below low income and had education at or below 12th grade
raised serious concerns about drug safety in this patient popula-
tion. The increase in the use of hydrocodone and oxycodone
indicated a need to better assess the efﬁcacy and safety associ-
ated with these drugs among individuals with back pain.
PPN9
PRESCRIPTION OF NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS AND MUSCLE RELAXANTS FOR BACK PAIN IN THE
UNITED STATES
Luo X1, Pietrobon R2, Curtis L3, Hey L1
1Duke University Medical Center, Durham, NC, USA; 2Duke
University Medical Center, Durham, NC, USA
Secondary analysis of the 2000 Medical Expenditure Panel
Survey (MEPS). OBJECTIVE: To examine national prescription
patterns of non-steroidal anti-inﬂammatory drugs (NSAIDs) and
muscle relaxants among individuals with back pain in the United
States. Summary of Background Data. There is a lack of infor-
mation on national prescription patterns of NSAIDs and muscle
relaxants among individuals with back pain in the US.
METHODS: Traditional NSAIDs, cyclooxygenase-2-speciﬁc
(COX-2) inhibitors and muscle relaxants were investigated. Indi-
viduals with back pain were stratiﬁed by socio-demographic
characteristics and geographical regions. For each medication
category, overall prescribing frequency was compared across dif-
ferent strata and individual drug prescription was analyzed.
RESULTS: Traditional NSAIDs, COX-2 inhibitors and muscle
relaxants respectively accounted for 16.3%, 10% and 18.5% of
total prescriptions for back pain in 2000. Among individual
drugs, ibuprofen and naproxen accounted for most of the pre-
scriptions for traditional NSAIDs (60%), whereas two-thirds 
of the prescriptions for muscle relaxants were attributable to
cyclobenzaprine, carisoprodol and methocarbamol. Prescription
of COX-2 inhibitors or muscle relaxants demonstrated wide
variations across different regions. Several individual character-
istics including age, race and educational level were associated
with the prescription of some of the medications. CONCLU-
SIONS: Neither traditional NSAIDs, nor COX-2 inhibitors, 
nor muscle relaxants dominated prescriptions for back pain.
However, a small number of individual drugs were attributable
to most of the prescriptions for traditional NSAIDs or muscle
relaxants. The prescription of some of the medications demon-
strated wide variations across different regions or different racial
and educational groups. More studies are needed to understand
why the variations occurred and how to standardize the 
prescriptions.
METHODS
METHODS—Cost Related Studies
PMD1
COMPARISON OF GENERALIZED LINEAR MODELS 
AND ORDINARY LEAST-SQUARES REGRESSION FOR 
COST ESTIMATION
Ollendorf DA, Pedan A
PharMetrics Inc, Watertown, MA, USA
OBJECTIVES: To illustrate how use of generalized linear models
to analyze health care cost data may provide a better distribu-
tional ﬁt than commonly employed approaches (e.g., linear or
log-linear ordinary least squares [OLS] regression), and could
yield quantitatively and inferentially different conclusions.
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database, which includes integrated medical pharmacy
claims from 73 health plans nationwide. Patients with a diag-
nosis of intermittent claudication (ICD-9-CM 443.9x) who
newly started cilostazol or pentoxifylline therapy between June
1999–March 2002 were selected for analysis. Six-month pre-
treatment and follow-up periods were created in relation to the
ﬁrst observed prescription. Total costs of care during follow-up
were estimated based on health plan payments for medications
and services rendered, and were expressed in 2002 U.S. dollars.
Alternative multivariate approaches to analyzing total costs were
employed–an OLS model (log-linear) versus a generalized linear
model (GLM) with a log-link function and a gamma distribu-
tion. Covariates included demographic and other baseline/
pretreatment variables. Histograms of untransformed and log-
transformed costs were compared to gamma and normal distri-
butions; goodness-of-ﬁt assessments also were conducted. The
results of OLS (on a log-transformed outcome) and gamma GLM
models were compared. RESULTS: Analyses were conducted for
763 and 506 patients newly starting cilostazol and pentoxifylline
therapy respectively. The results of goodness-of-ﬁt testing
(deviance: 1489.5 vs. 1366.4 for degrees of freedom = 1,255)
indicated that the gamma GLM model approximated the cost
distribution most closely. Observed annual mean total costs were
$6238 and $5568 for cilostazol and pentoxifylline respectively;
application of the two models yielded different results—a non-
signﬁcant (p = 0.0620) treatment effect using log-linear OLS, and
